SynthesisFrontiers in oncology2021
The Clinical and Pathological Characteristics of Malignant Struma Ovarii: An Analysis of 144 Published Patients.
Synthesis in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Surgical approach and recurrence risk in struma ovarii: A retrospective and systematic analysis.Biomolecules & biomedicine · 2025Pooled it
- Highly Differentiated Follicular Carcinoma of Ovarian Origin: A Systematic Review of the Literature.Current oncology (Toronto, Ont.) · 2022Pooled it
- The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.Journal of ovarian research · 2022Pooled it
- Article
- Optimal Strategies for the Surgical and Long-Term Management of Malignant Struma Ovarii.Case reports in endocrinology · 2026Article
- A Case Report of Malignant Struma Ovarii With Papillary Thyroid Carcinoma.Clinical case reports · 2025Article
- Malignant Struma Ovarii: A Rare Manifestation of Ectopic Thyroid Cancer.JCEM case reports · 2025Article
- A retrospective case series at a tertiary hospital in china: ultrasonographic features of Struma ovarii.BMC cancer · 2025Article
- Clinicopathological and imaging features of struma ovarii: a retrospective study.Frontiers in oncology · 2025Article
- Papillary Thyroid Carcinoma Arising Within a Mature Ovarian Cystic Teratoma: A Case Report.Case reports in endocrinology · 2025Article
- The Role of Radioiodine Therapy in Differentiated Thyroid Cancer Arising from Struma Ovarii: A Systematic Review.Journal of clinical medicine · 2024Review
- Malignant struma ovarii in pregnancy: A case report.Gynecologic oncology reports · 2024Article
- Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin WithJCEM case reports · 2024Article
- Diagnostic Value of Nuclear Hybrid Imaging in Malignant Struma Ovarii: A Systematic Review of Case Reports.Diagnostics (Basel, Switzerland) · 2024Review
- Teratoma combined with struma ovarii and sarcomatoid carcinoma: a case report and review of the literature.BMC women's health · 2024Review
- Clinical use of thyroglobulin: not only thyroid cancer.Endocrine · 2024Review
- Clinical Manifestations of Malignant Struma Ovarii: A Retrospective Case Series in a Tertiary Hospital in Korea.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Struma Ovarii during Pregnancy.Diagnostics (Basel, Switzerland) · 2024Review
- A case report of malignant struma ovarii with papillary thyroid carcinoma.Clinical case reports · 2024Article
- Presentation and treatment of two cases of malignant struma ovarii.BMC women's health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to summarize the clinical and pathologic characteristics of malignant struma ovarii to facilitate the early diagnosis and treatment of this disease. All 144 patients were females from 27 countries. The mean age of the patients at diagnosis was 42.6 years. Overall, 35.71% of the patients underwent unilateral oophorectomy, 58.57% of the patients underwent bilateral oophorectomy, 5.72% of the patients were not ovariectomized, and 38.57% of the patients received radioactive iodine treatment with an average dose of 158.22 mCI each time. "Impure" types accounted for 70.19% of the cases, while pure types accounted for 29.81% of the cases. Among these cases, papillary thyroid carcinoma accounted for 50.00%, follicular thyroid carcinoma accounted for 26.47%, follicular variant of papillary thyroid carcinoma accounted for 18.63%, papillary and follicular mixed thyroid carcinoma accounted for 2.94%, anaplastic carcinoma accounted for 0.98%, and medullary carcinoma accounted for 0.98%. In total, 21 patients (51.22%) had elevated CA125. More than half of the patients (51.94%) had metastasis outside the ovary. The most common metastatic site was the pelvic cavity. The misdiagnosis rate was 17.27%. Mortality was related to metastasis and the cancer type. Gene mutations were found in the NRAS, KRAS, BRAF, and KIT genes and were similar to those in thyroid carcinoma, but some patients (37.5%) did not exhibit any gene mutations. Regardless of the treatment received, the survival rate is high. Treatment could initially include ovariectomy; however, in cases with metastasis and iodine uptake of the metastatic tumor, thyroidectomy, radioactive iodine therapy, and thyroid hormone inhibiting therapy are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.